Thymalin
A peptide extract of calf thymus developed at the St. Petersburg Institute of Bioregulation and Gerontology. In one 6-8-year cohort run by the developing group, mortality was reported about two times lower than in controls; no independent human trial exists. Often paired with Epithalon.
Medical Disclaimer: The information on this page is for educational and research purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
What Is Thymalin?
Thymalin is a natural peptide complex extracted and purified from calf thymus gland, developed at the St. Petersburg Institute of Bioregulation and Gerontology -- the same institute responsible for Epithalon.
The thymus gland is the primary organ of immune education, responsible for producing and maturing T-lymphocytes. It undergoes progressive involution (shrinkage) starting in early adulthood, with significant functional decline by age 40-50. This thymic involution is considered one of the key drivers of immunosenescence -- the age-related deterioration of immune function that increases cancer risk, susceptibility to infection, and autoimmune phenomena.
Mechanism of Action
- Thymopoiesis restoration -- Thymalin stimulates proliferation and differentiation of T-cell precursors, effectively restoring the thymus's ability to produce mature T-lymphocytes
- T-cell subset normalisation -- restores the balance between CD4+ helper and CD8+ cytotoxic T-cells, which becomes dysregulated with age
- Cytokine regulation -- normalises production of key immune signalling molecules including IL-2, IL-6, and interferon-gamma
- Bone marrow support -- stimulates haematopoiesis, supporting production of immune precursor cells
The Two-Peptide Protocol: Epithalon + Thymalin
The St. Petersburg group proposed two master regulators of biological ageing:
- The neuroendocrine system -- regulated by Epithalon via the pineal gland
- The immune system -- regulated by Thymalin via thymic restoration
In the group's cohort of 266 older adults, followed for 6-8 years with the peptides given during the first 2-3 years, mortality was reported 2.0-2.1 times lower with Thymalin, 1.6-1.8 times lower with Epithalamin and 2.5 times lower with both, compared with controls. The report comes from the group that developed the peptides, the abstract does not describe how people were assigned to groups, and no independent team has repeated it.
Practical Protocol
Cycle structure: 10mg/day subcutaneous for 10 consecutive days, twice yearly (spring and autumn). The community convention runs it in the same window as Epithalon; a separate window makes it possible to tell which peptide caused a side effect. Allow at least 3 months between cycles.
Stacking Interactions
How Thymalin interacts with other compounds
The pairing comes from the St. Petersburg group. In its 6-8-year cohort of 266 older adults, mortality was reported 2.5 times lower with both peptides than in controls. Running both in the same 10-day window is the community convention; separate windows make it possible to tell which one caused a side effect.
Protocols using Thymalin
Evidence-graded stacks that include this compound
Safety Profile — Tier B
Generally safe — moderate evidence
Contraindications
- ●Autoimmune diseases - may amplify immune response
- ●Organ transplant recipients on immunosuppression
- ●Pregnancy - insufficient data
Side Effects
- ●Generally well-tolerated in all published clinical studies
- ●Mild local reaction at injection site
- ●Rare: mild fever (immune activation response)